PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.71
Negative D/E while CRVO shows 1.57. Joel Greenblatt would look for hidden assets and restructuring catalysts.
-8.61
Both companies show net cash positions. Charlie Munger would investigate if industry economics justify such conservative capitalization.
-4.36
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
0.07
Current ratio exceeding 1.5x CRVO's 0.00. Charlie Munger would verify if this advantage translates to better supplier terms.
No Data
No Data available this quarter, please select a different quarter.